Neureka! set to release first product to market.

• Author: Louiseize, Kelly
• Position: SPECIAL REPORT: BIOTECHNOLOGY

Greater Sudbury's first biotechnology project is on its way to commercialization.

Clinical tests are nearing completion as a highly effective cholesterol marker kit developed in Northern Ontario is prepared for the world market.

Results from a 40-month initiative between the Northern Centre for Biotechnology and Clinical Research (Neureka!) and Finland's University of Turku have come to bear with a cholesterol marker kit.

"At this point we are almost finished the research and development and we are in the process to approve a specific type of certification called ISO for medical devices," says Dr. Magdy Basta, president and CEO of Neureka!.

Currently, conventional test identifying cholesterol disorders are not effective markers, but the test kit, developed by Sudbury and Turku resident scientists in Europe, has a success rate of over 90 per cent.

Specifically, the kit targets bad cholesterol, which is found to exhibit numerous lesions on the artery walls that lead to heart disease, stroke and other cardiovascular disorders. Blood samples taken from at least 200 patients identified cholesterol targets within two hours.

National and international hospitals, institutions and medical laboratories such as MDS Diagnostic Services will be the end users.

By the end of the year, Basta will have a better idea as to who will distribute and manufacture the kits. It will take a few years before distributors create a demand.

Right now Basta is in communication with distributors in Finland, Germany, South America and the United States. But before they are even considered, small manufacturing facilities must be courted. Basta...